Document Detail


Outcomes after transcatheter aortic valve implantation with both Edwards-SAPIEN and CoreValve devices in a single center: the Milan experience.
MedLine Citation:
PMID:  21087745     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the 2 commercially available valves with 3 delivery approaches selected in a stepwise fashion.
BACKGROUND: Limited data exist on the results of a comprehensive TAVI program using different valves with transfemoral, transapical, and transaxillary approaches for treatment of severe aortic stenosis.
METHODS: We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a single center with either the Medtronic-CoreValve (MCV) (Medtronic, Minneapolis, Minnesota) or Edwards-SAPIEN valve (ESV) (Edwards Lifesciences, Irvine, California) delivered via the transfemoral or transaxillary approaches and ESV via the transapical approach.
RESULTS: A total of 137 patients underwent TAVI: 107 via transfemoral (46 MCV and 61 ESV), 15 via transaxillary (12 MCV and 3 ESV), and 15 via transapical approach. After the transfemoral approach, the procedural success rate was 93.5%, and major vascular complication rate was 20.6%. No intra-procedural deaths occurred. The procedural success rates of transapical and transaxillary approaches were 86.6% and 93.3%, respectively. The 30-day mortality rate was 0.9% in transfemoral group and 13.3% in transapical, and no deaths occurred after transaxillary access. Cumulative death rate at 6 months was 12.2% in transfemoral, 26.6% in transapical, and 18.2% in transaxillary groups. At multivariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area, and history of cerebrovascular disease were significantly associated with an increased risk of major adverse cardiac and cerebrovascular events.
CONCLUSIONS: Routine TAVI using both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients with good overall procedural success rates and 30-day and 6-month outcomes.
Authors:
Cosmo Godino; Francesco Maisano; Matteo Montorfano; Azeem Latib; Alaide Chieffo; Iassen Michev; Rasha Al-Lamee; Marta Bande; Marco Mussardo; Francesco Arioli; Alfonso Ielasi; Micaela Cioni; Maurizio Taramasso; Irina Arendar; Antonio Grimaldi; Pietro Spagnolo; Alberto Zangrillo; Giovanni La Canna; Ottavio Alfieri; Antonio Colombo
Related Documents :
2774715 - The porcine bioprosthetic heart valve: experience at 15 years.
21053745 - Mid-term follow up of triple valve surgery in a western community: predictors of survival.
2960525 - Value of the regurgitant volume to end diastolic volume ratio to predict the regression...
7953265 - Simple flap valve for continent urinary diversion.
11209625 - Preinduction cervical ripening techniques compared.
2645445 - Asymptomatic severe carotid stenosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  3     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-22     Completed Date:  2011-03-04     Revised Date:  2012-08-29    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1110-21     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Affiliation:
Interventional Cardiology Unit, San Raffaele Institute, Milan, Italy. cosmogodino@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Aortic Valve Stenosis / mortality,  therapy*
Axillary Artery
Female
Femoral Artery
Heart Catheterization / adverse effects,  instrumentation*,  methods,  mortality
Heart Valve Prosthesis*
Heart Valve Prosthesis Implantation / adverse effects,  instrumentation*,  methods,  mortality
Hospital Mortality
Humans
Italy
Logistic Models
Male
Prosthesis Design
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Survival Analysis
Survival Rate
Thoracotomy
Time Factors
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The global experience with percutaneous aortic valve replacement.
Next Document:  Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis.